A new R&D center, spread over 12,000m2 area, is being established in Beijing to ensure focus on protein technology, biology and pharmacology research activities.
This will increase the overall seating capacity from 130 to 200 with in-built flexibility for future expansion.
Commenting on the development, Novo Nordisk chief science officer and executive vice president Mads Krogsgaard Thomsen inferred that the investment in the new R&D facility augurs well for both the company and China.
"Novo Nordisk recognises the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world," Thomsen added.
The company’s existing research center in Beijing contributes to it’s portfolio in the areas of diabetes and biopharmaceutical target disease areas.